Recruiting Pulmonary Embolism Studies in San Antonio
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female pediatric participants with...
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate. The main questions it aims to answer are: * Does AP301 lo...
Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
The primary purpose of this study is to evaluate the efficacy, durability, and mechanism of HbA1c reduction produced by the combination of pioglitazone plus tirzepatide compared to metformin plus sita...
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
The purpose of this study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the possible treatment of severe alopecia areata. Alopecia areata is a condition that...
Placement of Antibiotic Powder in Wounds During the Emergency Room
This is the first prospective controlled study to determine whether the topical application of vancomycin powder reduces infection-related complications when applied to open fracture injuries in the a...
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
This study will evaluate the efficacy and safety of plozasiran in approximately 140 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP)...
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition. There...
Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)
The overall objective of this study is to determine the safety of PEG fusion when used with primary repair or reconstruction in patients with an acute upper extremity peripheral nerve injury. PEG is s...
About Pulmonary Embolism Clinical Trials in San Antonio
Pulmonary embolism (PE) is a blockage of an artery in the lungs, usually caused by blood clots that travel from the deep veins of the legs. It can be life-threatening and requires immediate medical attention. Treatment includes anticoagulants and in severe cases, thrombolytic therapy.
There are currently 8 pulmonary embolism clinical trials recruiting participants in San Antonio, TX. These studies are seeking a combined 1,595 participants. Research is being sponsored by Vanda Pharmaceuticals, Alebund Pharmaceuticals, The University of Texas Health Science Center at San Antonio and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Pulmonary Embolism Clinical Trials in San Antonio — FAQ
Are there pulmonary embolism clinical trials in San Antonio?
Yes, there are 8 pulmonary embolism clinical trials currently recruiting in San Antonio, TX. Browse the studies on this page to find one that fits.
How do I join a clinical trial in San Antonio?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Antonio research site will contact you about next steps.
Are clinical trials in San Antonio free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Antonio studies also compensate for your time and travel.
What pulmonary embolism treatments are being tested?
The 8 active trials in San Antonio are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary embolism.
Data updated March 2, 2026 from ClinicalTrials.gov